Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Outstanding (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Shares Outstanding for 14 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 117.65% year-over-year to $18.3 million, compared with a TTM value of $18.3 million through Dec 2025, up 117.65%, and an annual FY2025 reading of $18.3 million, up 117.65% over the prior year.
  • Shares Outstanding was $18.3 million for Q4 2025 at Karyopharm Therapeutics, up from $8.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $114.5 million in Q3 2023 and bottomed at $7.5 million in Q4 2022.
  • Average Shares Outstanding over 5 years is $48.8 million, with a median of $46.7 million recorded in 2021.
  • The sharpest move saw Shares Outstanding skyrocketed 102591.02% in 2021, then crashed 93.19% in 2024.
  • Year by year, Shares Outstanding stood at $75.7 million in 2021, then crashed by 90.04% to $7.5 million in 2022, then rose by 1.5% to $7.7 million in 2023, then rose by 9.82% to $8.4 million in 2024, then surged by 117.65% to $18.3 million in 2025.
  • Business Quant data shows Shares Outstanding for KPTI at $18.3 million in Q4 2025, $8.7 million in Q3 2025, and $8.6 million in Q2 2025.